Senopsys/BMS 2016 AAPS Presentation – A Structured Taste Masking Process for Developing Palatable Pediatric Chewable Tablets
Senopsys and Bristol-Myers Squibb presented results of a process used to develop palatable pediatric chewable tablet formulations for two APIs with different taste masking challenges. Development followed a two-stage design: Stage 1 – Taste Assessment to quantify the taste masking challenge. Stage 2 – Taste Optimization following a sensory-directed formulation development approach.
Click here to download the presentation
Do You Have A Taste Masking Challenge?
Are you faced with the need to develop a palatable drug product to support clinical trials or commercial development? Our scientists are expert in both taste assessment and taste masking.
We use our experienced GCP-compliant taste panels and analytic tools to quantify the taste masking challenge and guide formulation development. And we apply a structured, sensory-directed development approach pioneered in the food industry to create palatable, taste-masked drug formulations for liquids, powders and solids.
Talk to our team about your specific formulation challenge.
Palatability should never be the reason a medicine fails.
About the Authors
Jeff Worthington is President and Founder of Senopsys, established in 2006 to advance the development of palatable, patient-accepted medicines. With over three decades of experience, he advances approaches to taste masking that help ensure palatability does not become a barrier to clinical or commercial success.
David Tisi, Technical Director at Senopsys, is an expert in sensory-directed pharmaceutical development. He applies GCP-compliant human taste assessment, analytical tools, and formulation strategies to quantify and address complex palatability challenges across dosage forms and development stages.